Novartis AG

NOVN

CH0012005267

Pharmaceuticals

Real-time Estimate Cboe Europe Other stock markets 12:03:37 2026-03-17 pm EDT			5-day change	1st Jan Change
121.69 ^CHF	+0.21%		-0.10%	+11.20%

02:48am	Novartis Raises $11 Billion to Fund Avidity Biosciences Deal	MT
Mar. 16	Novartis Unit Files to Sell Notes to Repay Loan for Avidity Biosciences Acquisition	MT

NOVARTIS AG : UBS reiterates its Neutral rating

Published on 02/06/2026 at 06:19 am EST

MarketScreener with dpa-AFX Analyser

NOVARTIS AG

+0.24%

Matthew Weston from UBS retains his Neutral opinion on the stock. The target price remains set at CHF 116.

Latest news about Novartis AG

02:48am	Novartis Raises $11 Billion to Fund Avidity Biosciences Deal	MT
Mar. 16	Novartis Unit Files to Sell Notes to Repay Loan for Avidity Biosciences Acquisition	MT
Mar. 16	Novartis Issues Debt Offering to Help Fund $12 Billion Acquisition of Avidity Biosciences	DJ
Mar. 16	Julius Baer CEO tops highest pay at UBS	RE
Mar. 16	Novartis board of directors has decided to launch a new share buyback program	RE
Mar. 16	Swiss stocks - Factors to watch on March 16	RE
Mar. 16	Novartis Wins US FDA Nod for Hidradenitis Suppurativa Treatment for Patients Over 12 Years Old	MT
Mar. 13	Novartis Announces FDA Approval for Cosentyx for Pediatric Patients with Moderate to Severe Hidradenitis Suppurativa	CI
Mar. 13	Novartis Gets FDA Approval for Cosentyx in Pediatric Patients	MT
Mar. 13	Novartis Cosentyx(R) receives FDA approval for pediatric patients aged 12+ with moderate to severe hidradenitis suppurativa	DJ
Mar. 12	Viatris settles lawsuit over use of woman's 'immortal' cells to power drug research	RE
Mar. 12	Mesoblast Limited Appoints Dr. Teresa Montagut As Head Of Clinical Development And Medical Affairs	CI
Mar. 12	Ipsen Announces Executive Changes	CI
Mar. 10	Swiss stocks - Factors to watch on March 10	RE
Mar. 09	Global drugmakers rush to boost US presence as tariff threat looms	RE

Novartis AG is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales break down by therapeutic area as follows: - oncology (30.9%); - immunology (18.9%); - cardiovascular, renal and metabolic diseases (16.4%); - neuroscience (11%). The remaining net sales (22.8%) are from contract manufacturing of pharmaceutical products. At the end of 2025, Novartis AG had over 31 production sites worldwide. Net sales are distributed geographically as follows: Switzerland (2.6%), Europe (28.1%), the United States (42.8%), Asia/Africa/Australasia (19.8%), Canada and Latin America (6.7%).

Employees

75,267

Sector

Pharmaceuticals

Calendar

Apr. 28 - Earnings release - Q1 2026

More about the company